Niki BioSolutions, Inc. (NIKI) EBITDA Margin (2024 - 2025)
Niki BioSolutions' (NIKI) quarterly EBITDA Margin came in at 228.04% in Q4 2025, up 26339.0% YoY from N/an in Q4 2024, and up 214.59% on a QoQ basis from 199.0% in Q3 2025.
Niki BioSolutions, Inc. (NIKI) EBITDA Margin (2024 - 2025) Analysis & Trends
Niki BioSolutions (NIKI) has 2 years of EBITDA Margin data on file, last reported at 228.04% in Q4 2025.
- Quarterly EBITDA Margin rose 26339.0% year-over-year to 228.04% in Q4 2025, while the trailing twelve-month figure through Nov 2025 was 29.7% (changed N/A YoY) and the FY2025 annual result came in at 101.82%, down 6761.0% from the prior year.
- EBITDA Margin climbed to 228.04% in Q4 2025, from 199.0% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 228.04% in Q4 2025 to a low of 199.0% in Q3 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2025 | 228.04% |
| Aug 31, 2025 | -199.00% |
| Nov 30, 2024 | -35.35% |
| Aug 31, 2024 | -71.86% |